Dapoxetine Delay: J&J’s Premature Ejaculation Drug “Not Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Alza says it will continue the global development program and address FDA’s questions.
You may also be interested in...
Reviving The Premature Ejaculation Field; Sciele/Plethora Start Final Phase III
Recent approval of Johnson & Johnson’s dapoxetine in Sweden and Finland put field back on the radar.
Reviving The Premature Ejaculation Field; Sciele/Plethora Start Final Phase III
Recent approval of Johnson & Johnson’s dapoxetine in Sweden and Finland put field back on the radar.
J&J Pipeline On Track; Tapentadol Filing Expected This Week
Firm reports fourth quarter pharmaceutical sales of $6.4 billion worldwide and $3.9 billion in the U.S.